The effects of shortening lactoferrin derived peptides against tumour cells, bacteria and normal human cells

Journal of Peptide Science

Volumn 10, Issue 1, 2004, Pages 37-46

  Yang, Nannan ^a   Strøm, Morten B ^a   Mekonnen, Seble M ^a   Svendsen, John S ^a   Rekdal, Øystein ^a  

^a UNIVERSITY OF TROMSØ   (Norway)

Author keywords

Anticancer peptides; Antimicrobial peptides; Antitumour peptides; Lactoferrin; Lytic peptides; Tumouricidal peptides

Indexed keywords

ALANYLTRYPTOPHYLARGINYLLYSYLALANYLPHENYLALANYLARGINYLTRYPTOPHYLALANYLLYS YLARGINYLMETHIONYLLEUCYLLYSYLLYSYLALANYLALANINE; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ARGINYLLYSYLALANYLPHENYLALANYLARGINYLTRYPTOPHYLALANYLLYSYLARGINYLMETHION YLLEUCYLLYSYLLYSYLALANYLALANINE; ARGINYLPHENYLALANYLLYSYLARGINYLTRYPTOPHYLTRYPTOPHYLLYSYLARGINYLMETHIONYL LEUCYLLYSYLLYSINE; LACTOFERRIN; LACTOFERRIN DERIVATIVE; LYSYLALANYLPHENYLALANYLARGINYLTRYPTOPHYLALANYLLYSYLARGINYLMETHIONYLLEUCY LLYSYLLYSYLALANYLALANINE; PEPTIDE DERIVATIVE; PROLYLALANYLTRYPTOPHYLARGINYLLYSYLALANYLPHENYLALANYLARGINYLTRYPTOPHYLALA NYLLYSYLARGINYLMETHIONYLLEUCYLLYSYLLYSYLALANYLALANINE; TRYPTOPHAN; TRYPTOPHYLARGINYLLYSYLALANYLPHENYLALANYLARGINYLTRYPTOPHYLALANYLLYSYLARGI NINE; TRYPTOPHYLARGINYLLYSYLALANYLPHENYLALANYLARGINYLTRYPTOPHYLALANYLLYSYLARGI NYLMETHIONINE; TRYPTOPHYLARGINYLLYSYLALANYLPHENYLALANYLARGINYLTRYPTOPHYLALANYLLYSYLARGI NYLMETHIONYLLEUCINE; TRYPTOPHYLARGINYLLYSYLALANYLPHENYLALANYLARGINYLTRYPTOPHYLALANYLLYSYLARGI NYLMETHIONYLLEUCYLLYSINE; TRYPTOPHYLARGINYLLYSYLALANYLPHENYLALANYLARGINYLTRYPTOPHYLALANYLLYSYLARGI NYLMETHIONYLLEUCYLLYSYLLYSINE; TRYPTOPHYLARGINYLLYSYLALANYLPHENYLALANYLARGINYLTRYPTOPHYLALANYLLYSYLARGI NYLMETHIONYLLEUCYLLYSYLLYSYLALANINE; TRYPTOPHYLARGINYLLYSYLALANYLPHENYLALANYLARGINYLTRYPTOPHYLALANYLLYSYLARGI NYLMETHIONYLLEUCYLLYSYLLYSYLALANYLALANINE; TRYPTOPHYLARGINYLLYSYLPHENYLALANYLARGINYLTRYPTOPHYLLYSYLARGINYLMETHIONYL LEUCYLLYSYLLYSINE; TRYPTOPHYLARGINYLPHENYLALANYLARGINYLTRYPTOPHYLARGINYLLYSINAMIDE; TRYPTOPHYLARGINYLPHENYLALANYLARGINYLTRYPTOPHYLARGINYLMETHIONYLLYSINAMIDE; TRYPTOPHYLARGINYLPHENYLALANYLARGINYLTRYPTOPHYLARGINYLTRYPTOPHANAMIDE; TRYPTOPHYLARGINYLPHENYLALANYLARGINYLTRYPTOPHYLLARGINYLMETHIONYLLEUCYLLYS INAMIDE; TRYPTOPHYLARGINYLPHENYLALANYLARGINYLTRYPTOPHYLLYSYLARGINYLMETHIONYLLEUCY LLYSINAMIDE; TRYPTOPHYLPHENYLALANYLLYSYLARGINYLARGINYLTRYPTOPHYLLYSYLARGINYLMETHIONYL LEUCYLLYSYLLYSINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACTERIAL STRAIN; CHEMICAL MODIFICATION; CHEMICAL PARAMETERS; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG CONFORMATION; DRUG DESIGN; DRUG SELECTIVITY; DRUG STRUCTURE; ESCHERICHIA COLI; FIBROBLAST; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEMOLYSIS; HYDROPHOBICITY; MOLECULAR SIZE; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STRUCTURE ACTIVITY RELATION; TUMOR CELL LINE;

AMINO ACID SEQUENCE; ANIMALS; ANTI-INFECTIVE AGENTS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; ESCHERICHIA COLI; HUMANS; LACTOFERRIN; MICE; MODELS, MOLECULAR; NEOPLASMS; PEPTIDES; STAPHYLOCOCCUS AUREUS; STRUCTURE-ACTIVITY RELATIONSHIP;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; NEGIBACTERIA; POSIBACTERIA; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS;

EID: 0347766076     PISSN: 10752617     EISSN: None     Source Type: Journal    
DOI: 10.1002/psc.470     Document Type: Article

References (33)

1. Epand RM, Vogel HJ. Diversity of antimicrobial peptides and their mechanisms of action. Biochim. Biophys. Acta 1999; 1462: 11-28.
2. Hancock RE. Cationic peptides: effectors in innate immunity and novel antimicrobials. Lancet Infect. Dis. 2001; 1: 156-164.
3. Devine DA, Hancock RE. Cationic peptides: distribution and mechanisms of resistance. Curr. Pharm. Des. 2002; 8: 703-714.
4. Vogel HJ, Schibli DJ, Jing W, Lohmeier-Vogel EM, Epand RF, Epand RM. Towards a structure-function analysis of bovine lactoferricin and related tryptophan- and arginine-containing peptides. Biochem. Cell Biol. 2002; 80: 49-63.
5. Strøom MB, Haug BE, Rekdal øO, Skar ML, Stensen W, Svendsen JS. Important structural features of 15-residue lactoferricin derivatives and methods for improvement of antimicrobial activity. Biochem. Cell Biol. 2002; 80: 65-74.
6. Cruciani RA, Barker JL, Zasloff M, Chen HC, Colamonici O. Antibiotic magainins exert cytolytic activity against transformed cell lines through channel formation. Proc. Natl Acad. Set. USA 1991; 88: 3792-3796.
7. Baker MA, Maloy WL, Zasloff M, Jacob LS. Anticancer efficacy of magainin2 and analogue peptides. Cancer Res. 1993; 53: 3052-3057.
8. Shin SY, Kang JH, Hahm KS. Structure-antibacterial, antitumor and hemolytic activity relationships of cecropin A-magainin 2 and cecropin A-melittin hybrid peptides. J. Pept. Res. 1999; 53: 82-90.
9. Shin SY, Kang JH, Jang SY, Kim Y, Kim KL, Hahm K. Effects of the hinge region of cecropin A(1-8)-magainin 2(1-12), a synthetic antimicrobial peptide, on liposomes, bacterial and tumor cells. Biochim. Biophys. Acta 2000; 1463: 209-218.
10. Rinaldi AC, Mangoni ML, Rufo A, Luzi C, Barra D, Zhao H, Kinnunen PK, Bozzi A, Di Giulio A, Simmaco M. Temporin L: antimicrobial, hemolytic, cytotoxic activities and effects on membrane permeabilization in lipid vesicles. Biochem. J. 2002; 22: 91-100.
11. Shin SY, Lee SH, Yang ST, Park EJ, Lee DG, Lee MK, Eom SH, Song WK, Kim Y, Hahm KS, Kim JI. Antibacterial, antitumor and hemolytic activities of alpha-helical antibiotic peptide, P18 and its analogs. J. Pept. Res. 2001; 58: 504-514.
12. Utsugi T, Schroit AJ, Connor J, Bucana CD, Fidler IJ. Elevated expression of phosphatidylserine in the outer membrane leaflet of human tumor cells and recognition by activated human blood monocytes. Cancer Res. 1991; 51: 3062-3066.
13. Chen HM, Wang W, Smith D, Chan SC. Effects of the anti-bacterial peptide cecropin B and its analogs, cecropins B-1 and B-2, on liposomes, bacteria, and cancer cells. Biochim. Biophys. Acta 1997; 1336: 171-179.
14. Chan SC, Hui L, Chen HM. Enhancement of the cytolytic effect of anti-bacterial cecropin by the microvilli of cancer cells. Anticancer Res. 1998; 18: 4467-4474.
15. Johnstone SA, Gelmon K, Mayer LD, Hancock RE, Bally MB. In vitro characterization of the anticancer activity of membrane-active cationic peptides. I. Peptide-mediated cytotoxicity and peptide-enhanced cytotoxic activity of doxorubicin against wild-type and p-glycoprotein over-expressing tumor cell lines. Anticancer Drug Des. 2000; 15: 151-160.
16. Yang N, Stensen W, Svendsen JS, Rekdal øO. Enhanced antitumor activity and selectivity of lactoferrin-derived peptides. J. Pept. Res. 2002; 60: 187-197.
17. Eliassen LT, Berg G, Sveinbjøornsson B, Vorland L, Svendsen JS, Rekdal øO. Evidence for direct antitumor mechanism of action by bovine lactoterricin. Anticancer Res. 2002; 22: 2703-2710.
18. Yang N, Lejon T, Rekdal øO. Antitumor activity and specificity as a function of substitutions in the lipophilic sector of helical lactoferrin-derived peptide. J. Pept. Sci. 2003; 9: 300-311.
19. Strøm MB, Rekdal øO, Svendsen JS. Antimicrobial activity of short arginine- and tryptophan-rich peptides. J. Pept. Sci. 2002; 8: 431-437.
20. Dathe M, Schumann M, Wieprecht T, Winkler A, Beyermann M, Krause E, Matsuzaki K, Murase O, Bienert M. Peptide helicity and membrane surface charge modulate the balance of electrostatic and hydrophobic interactions with lipid bilayers and biological membranes. Biochemistry 1996; 35: 12 612-12 622.
21. Seljelid R. A water-soluble aminated beta 1-3D-glucan derivative causes regression of solid tumors in mice. Biosci Rep. 1986; 6: 845-851.
22. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J. Immunol. 1986; 136: 2348-2357.
23. Amsterdam D. Susceptibility Testing of Antimicrobials in Liquid Media. In Antibiotics in Laboratory Medicine, 4th edn. Lorian V (ed). Willians and Wilkins: Baltimore, MD, 1996; 52-111.
24. Strøom MB, Rekdal øO, Svendsen JS. Antibacterial activity of 15-residue lactoferricin derivatives. J. Pept. Res. 2000; 56: 265-274.
25. Strøom MB, Rekdal øO, Svendsen JS. The effects of charge and lipophilicity on the antibacterial activity of undecapeptides derived from bovine lactoferricin. J. Pept. Sci. 2002; 8: 36-43.
26. Blondelle SE, Simpkins LR, Perez-Paya E, Houghten RA. Influence of tryptophan residues on melittin's hemolytic activity. Biochim. Biophys. Acta 1993; 1202: 331-336.
27. Strøom MB, Rekdal øO, Stensen W, Svendsen JS. Increased antibacterial activity of 15-residue murine lactoferricin derivatives. J. Pept. Res. 2001; 57: 127-139.
28. Kang JH, Lee MK, Kim KL, Hahm KS. Structure-biological activity relationships of 11-residue highly basic peptide segment of bovine lactoferrin. Int. J. Pept. Protein Res. 1996; 48: 357-363.
29. Minoux H, Chipot C. Cation-psi interactions in proteins: Can simple models provide an accurate description? J. Am. Chem. Soc. 1999; 121: 10 366-10 372.
30. Schibli DJ, Hwang PM, Vogel HJ. The structure of the antimicrobial active center of lactoferricin B bound to sodium dodecyl sulfate micelles. FEBS Lett. 1999; 446: 213-217.
31. Lyu PC, Sherman JC, Chen A, Kallenbach NR. Alpha-helix stabilization by natural and unnatural amino acids with alkyl side chains. Proc. Natl Acad. Sci. USA 1991; 88: 5317-5320.
32. Peck-Miller KA, Blake J, Cosand WL, Darveau RP, Fell HP. Structure-activity analysis of the antitumor and hemolytic properties of the amphiphilic alpha-helical peptide, C18G. Int. J. Pept. Protein Res. 1994; 44: 143-151.
33. Shin SY, Lee MK, Kim KL, Hahm KS. Structure-antitumor and hemolytic activity relationships of synthetic peptides derived from cecropin A-magainin 2 and cecropin A-melittin hybrid peptides. J. Pept. Res. 1997; 50: 279-285.